Massachusetts compromises on weaker Medicaid drug price disclosures

Responding to a biopharma industry lobbying campaign, the Massachusetts legislature has dialed back drug price and cost disclosure requirements. The requirements are part of provisions in the state budget that

Read the full 303 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE